Can a new drug stop inherited Alzheimer's in its tracks?

NCT ID NCT06384573

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study tests lecanemab, an antibody that targets amyloid plaques in the brain, in 40 people who carry a gene mutation that causes early-onset Alzheimer's. Participants previously received another anti-amyloid drug and will now receive lecanemab to see if it can fully clear amyloid plaques and slow cognitive decline. The goal is to understand whether aggressive amyloid removal can delay or prevent the onset of dementia in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lecanemab (also called BAN2401), given as an intravenous infusion
What this could lead to: If successful, this could show that removing amyloid plaques delays or slows the progression of inherited Alzheimer's disease, offering a potential treatment for this rare form.
What could go wrong: This is a small, open-label study with no placebo group, so results may be less reliable. The drug may not fully remove plaques or meaningfully slow the disease, and side effects like brain swelling or bleeding are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia familial Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE ALZHEIMER'S DISEASE, FAMILIAL DEMENTIA

Contacts and locations

Locations

Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States
Neuroscience Research Australia

Randwick, New South Wales, 2031, Australia
The National Hospital for Neurology and Neurosurgery

London, Greater London, WC1B 3BG, United Kingdom
University of Alabama in Birmingham

Birmingham, Alabama, 35294, United States
University of Washington

Seattle, Washington, 98195, United States
Washington University in St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.